背景:近年来,miRNA已经成为潜在的有价值的肿瘤标志物,它们的灵敏和准确的检测对于肿瘤的早期筛查和诊断至关重要。然而,miRNA的分析由于其短序列而面临重大挑战,易于降解,高度相似,在细胞中表达水平低,以及对体外研究环境的严格要求。因此,发展灵敏、高效的肿瘤标志物检测新方法对相关肿瘤的早期干预至关重要。
结果:建立了超灵敏的电化学/比色双模式自供电生物传感器平台,以通过多信号放大策略检测microRNA-21(miR-21)。制备了金纳米粒子(AuNPs)和VS4纳米片自组装三维纳米棒(VS4-Ns-Nrs),用于构建性能优异的酶生物燃料电池(EBFC)。采用Y形DNA纳米结构和催化发夹组装(CHA)的双信号放大策略,进一步提高了输出信号的强度和特异性。此外,电容器与EBFC匹配以产生放大数倍的瞬时电流,并且输出检测信号再次得到改善。同时,采用电化学和比色法进行双模式策略,以达到检测的准确性。检测的线性范围为0.001pg/mL至1000pg/mL,相对较低的检测限(LOD)为0.16fg/mL(S/N=3)。
结论:所建立的方法可以准确,灵敏地检测肺癌患者的标志物。为精准识别提供技术支持和数据参考。预计将为早期诊断提供敏感实用的新技术和方法,临床治疗,以及癌症和其他相关重大疾病的药物筛查。
BACKGROUND: In recent years, miRNAs have emerged as potentially valuable tumor markers, and their sensitive and accurate detection is crucial for early screening and diagnosis of tumors. However, the analysis of miRNAs faces significant challenges due to their short sequence, susceptibility to degradation, high similarity, low expression level in cells, and stringent requirements for in vitro research environments. Therefore, the development of sensitive and efficient new methods for the detection of tumor markers is crucial for the early intervention of related tumors.
RESULTS: An ultrasensitive electrochemical/colorimetric dual-mode self-powered biosensor platform is established to detect microRNA-21 (miR-21) via a multi-signal amplification strategy. Gold nanoparticles (AuNPs) and VS4 nanosheets self-assembled 3D nanorods (VS4-Ns-Nrs) are prepared for constructing a superior performance enzyme biofuel cell (EBFC). The double-signal amplification strategy of Y-shaped DNA nanostructure and catalytic hairpin assembly (CHA) is adopted to further improve enhance the strength and specificity of the output signal. In addition, a capacitor is matched with EBFC to generate an instantaneous current that is amplified several times, and the output detection signal is improved once more. At the same time, electrochemical and colorimetric methods are used for dual-mode strategy to achieve the accuracy of detection. The linear range of detection is from 0.001 pg/mL to 1000 pg/mL, with a relatively low limit of detection (LOD) of 0.16 fg/mL (S/N = 3).
CONCLUSIONS: The established method enables accurate and sensitive detection of markers in patients with lung cancer, providing technical support and data reference for precise identification. It is anticipated to offer a sensitive and practical new technology and approach for early diagnosis, clinical treatment, and drug screening of cancer and other related major diseases.